| Drug Name: | Cabergoline (81409-90-7) |
|---|---|
| PubChem ID: | 54746 |
| SMILES: | CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C |
| InchiKey: | KORNTPPJEAJQIU-KJXAQDMKSA-N |
| Therapeutic Category: | Anti-Dyskinesia Agents, Antineoplastic Agents, Antiparkinson Agents, Central Nervous System Agents, Dopamine Agents, Dopamine Agonists, Neurotransmitter Agents |
| Molecular Weight (dalton) | : | 451.615 |
| LogP | : | 3.1939 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 4 |
| Hydrogen Bond Donor Count | : | 2 |
| Total Polar Surface Area | : | 71.68 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Itraconazole (84625-61-6) | Hyperkinesia | Synergistic | Cabergoline is an ergot derivative that is metabolised by the cytochrome P450 isoenzyme CYP3A4,Itraconazole is a potent inhibitor of this isoenzyme | Cabergoline plasma concentration is increased during concomitant treatment with itraconazole |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category